Pharmacokinetics of anti-IL17A and anti-IL22 peptide-antibody bispecific genetic fusions in mice

International Immunopharmacology

Volumn 18, Issue 2, 2014, Pages 225-227

  Vugmeyster, Yulia ^a,b   Zhang, Yiqun ^a   Zhong, Xiaotian ^a   Wright, Jill ^a   Leung, Sheldon S ^a  

^a PFIZER INC   (United States)

^b ALEXION PHARMACEUTICALS INC   (United States)

Author keywords

Antibody; Bi functional pharmacokinetics; Bi specific; Genetic fusion; Peptide

Indexed keywords

IMMUNOGLOBULIN G1; INTERLEUKIN 17A ANTIBODY; INTERLEUKIN 22 ANTIBODY; PEPTIDE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; GENE FUSION; HEAVY CHAIN; IMMUNOASSAY; IN VITRO STUDY; LIGHT CHAIN; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEADY STATE; SWISS WEBSTER MOUSE;

ANTIBODY; BI-FUNCTIONAL PHARMACOKINETICS; BI-SPECIFIC; GENETIC FUSION; PEPTIDE;

ANIMALS; ANTIBODIES, BISPECIFIC; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-17; INTERLEUKINS; MALE; MICE; PEPTIDES; RECOMBINANT FUSION PROTEINS;

EID: 84891722960     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2013.11.013     Document Type: Article

References (15)

1. P. Chames, and D. Baty Bispecific antibodies for cancer therapy Curr Opin Drug Discov Dev 12 2009 276 283
2. N. Hollander Bispecific antibodies for cancer therapy Immunotherapy 1 2009 211 222
3. R. Kontermann Dual targeting strategies with bispecific antibodies mAbs 4 2012
4. A. Pluckthun, and P. Pack New protein engineering approaches to multivalent and bispecific antibody fragments Immunotechnology Int J Immunol Eng 3 1997 83 105 (Pubitemid 27356788)
5. X. Chen, J.L. Zaro, and W.C. Shen Pharmacokinetics of recombinant bifunctional fusion proteins Expert Opin Drug Metab Toxicol 8 2012 581 595
6. D.W. LaFleur, D. Abramyan, P. Kanakaraj, R.G. Smith, R.R. Shah, and G. Wang et al. Monoclonal antibody therapeutics with up to five specificities: functional enhancement through fusion of target-specific peptides mAbs 5 2013 208 218
7. X. Zhong, E. Kieras, E. Sousa, A. D'Antona, J.C. Baber, and T. He et al. Pyroglutamate and O-linked glycan determine functional production of anti-IL17A and anti-IL22 peptide-antibody bispecific genetic fusions J Biol Chem 288 2013 1409 1419
8. S.C. Liang, X.Y. Tan, D.P. Luxenberg, R. Karim, K. Dunussi-Joannopoulos, and M. Collins et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides J Exp Med 203 2006 2271 2279 (Pubitemid 44498362)
9. H.L. Ma, S. Liang, J. Li, L. Napierata, T. Brown, and S. Benoit et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation J Clin Invest 118 2008 597 607 (Pubitemid 351206549)
10. P. Miossec, T. Korn, and V.K. Kuchroo Interleukin-17 and type 17 helper T cells N Engl J Med 361 2009 888 898
11. S.B. Petkova, S. Akilesh, T.J. Sproule, G.J. Christianson, H. Al Khabbaz, and A.C. Brown et al. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease Int Immunol 18 2006 1759 1769 (Pubitemid 44884038)
12. Y. Vugmeyster, D. DeFranco, D.D. Pittman, and X. Xu Pharmacokinetics and lung distribution of a humanized anti-RAGE antibody in wild-type and RAGE -/- mice mAbs 2 2010 571 575
13. Y. Vugmeyster, P. Szklut, L. Tchistiakova, W. Abraham, M. Kasaian, and X. Xu Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms Int Immunopharmacol 8 2008 477 483
14. L. Diao, and B. Meibohm Pharmacokinetics and pharmacokinetic- pharmacodynamic correlations of therapeutic peptides Clin Pharmacokinet 52 2013 855 868
15. Y. Vugmeyster, X. Xu, F.P. Theil, L.A. Khawli, and M.W. Leach Pharmacokinetics and toxicology of therapeutic proteins: advances and challenges World J Biol Chem 3 2012 73 92